# Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

> **NCT00046748** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 484 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00046748
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2004-04
- **Final completion:** 2004-04
- **Target enrollment:** 484 (ACTUAL)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046748, "Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00046748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*